Mirum Pharmaceuticals is trading at $82.56, down 4.01%; no reliable report links the decline to the study data.
- The company announcement confirms an October 12 investor call to share topline results from its Phase 3 EXPAND study of LIVMARLI, but does not provide the results.
- Major indexes were nearly flat in the supplied market context.
- The price context shows a reversal from October 9’s 5.73% gain; no trading-volume information is available.